Vasopressin, measured as the stable marker copeptin, is considered as an established independent risk factor for diabetes, dyslipidemia, the metabolic syndrome, chronic kidney disease, cardiovascular disease, and premature death in the population [3, 5, 28–31]. Here, AVP is linked to metabolic syndrome.